Thalassemia Treatment Market Share

Statistics for the 2023 & 2024 Thalassemia Treatment market share, created by Mordor Intelligence™ Industry Reports. Thalassemia Treatment share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Thalassemia Treatment Industry

The thalassemia treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market Bluebird Bio, IONIS Pharmaceuticals, Novartis AG, Bellicum Pharmaceuticals, ApoPharma Inc, SG Pharma Pvt. Lmt. Acceleron Pharma, Inc., and Kiadis Pharma, Lonza Group Ltd.,

Thalassemia Treatment Market Leaders

  1. Bluebird Bio

  2. Novartis AG

  3. ApoPharma Inc

  4. Bellicum Pharmaceuticals

  5. Pfizer, Inc.

*Disclaimer: Major Players sorted in no particular order

Bluebird Bio, IONIS Pharmaceuticals, Novartis AG, Bellicum Pharmaceuticals, ApoPharma Inc, SG Pharma Pvt. Lmt. Acceleron Pharma, Inc., and Kiadis Pharma, Lonza Group Ltd.

Thalassemia Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)